The Saudi Arabia genetic testing market size reached USD 180.98 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 416.38 Million by 2033, exhibiting a growth rate (CAGR) of 9.70% during 2025-2033. The market is expanding due to rising demand for personalized medicine, government support under Vision 2030, and increasing awareness of preventive healthcare. Growth is further driven by advancements in genomic research, expanding DTC genetic testing services, and improved healthcare infrastructure. Investments in biotechnology and rising chronic diseases also fuel market progression, thus providing significant Saudi Arabia genetic testing market growth.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 180.98 Million |
Market Forecast in 2033 | USD 416.38 Million |
Market Growth Rate 2025-2033 | 9.70% |
Rising Demand for Personalized Medicine and Preventive Healthcare
The Saudi Arabia genetic testing market share is expanding due to the increasing demand for personalized medicine and preventive healthcare. With a rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, there is a growing emphasis on early detection and tailored treatment plans. According to a recent study, Saudi Arabia has a prevalence of diabetes at 27.19%, with a significant burden on females (26%) and the young adult population (19%), which has raised public health concerns to a great extent. An increase in diabetes mainly results from inactive lifestyles and improper diets. Additionally, the sudden equal prevalence of Type 1 and Type 2 diabetes could be due to genetic causes, highlighting the need for local genetic testing and tailored prevention methods. Since the rates of diabetes in Saudi Arabia are significantly higher than the international average, the Saudi genetic testing market could be vital for early detection and targeted measures to reduce this growing health emergency. Genetic testing enables healthcare providers to identify genetic predispositions to diseases, allowing for proactive interventions. The Saudi government’s Vision 2030 initiative further supports this trend by promoting advanced healthcare technologies and precision medicine. Additionally, heightened public awareness about the benefits of genetic screening, coupled with improving healthcare infrastructure, is driving market expansion. Private and public sector investments in genomic research and biotechnology are also accelerating advancements in this field. As a result, more clinics and hospitals are incorporating genetic testing services, making them accessible to a broader population and fostering market growth.
Expansion of Direct-to-Consumer (DTC) Genetic Testing Services
Another key trend in the market is the rapid expansion of direct-to-consumer (DTC) genetic testing services. Companies offering at-home DNA test kits are gaining popularity as consumers seek convenient and private ways to explore their ancestry, health risks, and wellness insights. The increasing internet penetration and e-commerce growth in the region have made it easier for individuals to order genetic tests online. A research report from the IMARC Group indicates that the size of the e-commerce market in Saudi Arabia was valued at USD 222.9 Billion in 2024. It is projected to grow to USD 708.7 Billion by 2033, reflecting a compound annual growth rate (CAGR) of 12.8% from 2025 to 2033. Thus, this is creating a positive Saudi Arabia genetic testing market outlook. Furthermore, rising health consciousness and disposable incomes are encouraging more individuals to invest in personalized genetic insights. Local and international DTC genetic testing providers are entering the Saudi market, offering competitive pricing and Arabic-language support to cater to regional preferences. Regulatory bodies are also working to establish guidelines to ensure the accuracy and ethical use of these tests. This trend is expected to continue growing as consumer interest in genetic data for health and lifestyle decisions increases.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the county and regional levels for 2025-2033. Our report has categorized the market based on type, technology, and application.
Type Insights:
The report has provided a detailed breakup and analysis of the market based on the type. This includes predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others.
Technology Insights:
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes cytogenetic testing and chromosome analysis, biochemical testing, and molecular testing (DNA sequencing and others).
Application Insights:
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Northern and Central Region, Western Region, Eastern Region, and Southern Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered | Predictive and Presymptomatic Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others |
Technologies Covered |
|
Applications Covered | Cancer Diagnosis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others |
Regions Covered | Northern and Central Region, Western Region, Eastern Region, Southern Region |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: